# NIH Reporter #5P50CA281701-04

The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer

**Recipient:** UNIVERSITY OF TX MD ANDERSON CAN CTR

**Award Amount:** $329,672.00
**Ceiling:** $329,672.00

**Awarded:** September 17, 2026

**Identifier:** 5P50CA281701-04

Award for a Phase IA trial of GRN-300, a SIK2 inhibitor, to assess its safety and efficacy in ovarian cancer, including its immunomodulatory effects and potential to enhance immune responses.

### Description

This project aims to complete a Phase IA trial of GRN-300, a SIK2 inhibitor, to evaluate its safety, pharmacokinetics, pharmacodynamics, and clinical activity, and to investigate its immunomodulatory effects in ovarian cancer treatment.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11412476)